Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.X-BODY BioSciences, a developer of human monoclonal antibody therapeutics, has received research grant from the US Department of the Treasury, under the Patient Protection and Affordable Care Act of 2010.
Subscribe to our email newsletter
Reviewed by scientists at the Department of Health and Human Services, the research grant has been awarded to X-BODY for its human monoclonal antibody therapeutic project targeting metastatic tumor stem cells.
The grant provides X-BODY with the maximum allowable 50% reimbursement of its qualified investment of ~$500,000 in this project.
The company claims that its therapeutic candidates target a kinase signaling pathway that is believed to mediate metastasis (invasion and spreading) of cancer tumor initiating stem cells.
X-BODY said that its pre-clinical candidates were discovered using a proprietary platform, based on a new screening technology allowing for rapid generation of human antibody therapeutics of high affinity and selectivity, via deep sequence interrogation of fully human DNA libraries.